Perigon Wealth Management LLC Buys 891 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Perigon Wealth Management LLC lifted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 180.7% during the fourth quarter, Holdings Channel reports. The fund owned 1,384 shares of the company’s stock after acquiring an additional 891 shares during the quarter. Perigon Wealth Management LLC’s holdings in IDEXX Laboratories were worth $768,000 as of its most recent filing with the SEC.

A number of other large investors have also recently added to or reduced their stakes in the stock. OFI Invest Asset Management acquired a new position in IDEXX Laboratories in the 3rd quarter valued at $25,000. E Fund Management Hong Kong Co. Ltd. bought a new position in shares of IDEXX Laboratories in the third quarter worth about $26,000. Valley National Advisers Inc. lifted its position in shares of IDEXX Laboratories by 84.6% during the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock worth $26,000 after purchasing an additional 22 shares during the last quarter. Altshuler Shaham Ltd bought a new stake in IDEXX Laboratories during the 4th quarter valued at approximately $26,000. Finally, Geo Capital Gestora de Recursos Ltd acquired a new stake in IDEXX Laboratories in the 3rd quarter valued at approximately $28,000. Institutional investors own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on IDXX. Piper Sandler cut IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price objective for the company. in a research report on Tuesday, January 30th. StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Wednesday, December 20th. Barclays upped their target price on IDEXX Laboratories from $605.00 to $655.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. JPMorgan Chase & Co. boosted their price target on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Finally, William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $591.50.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the business’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total value of $6,871,320.00. Following the transaction, the chief executive officer now owns 79,247 shares of the company’s stock, valued at $45,377,624.67. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the transaction, the chief executive officer now directly owns 79,247 shares in the company, valued at $45,377,624.67. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP George Fennell sold 8,198 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the completion of the sale, the senior vice president now directly owns 6,712 shares of the company’s stock, valued at approximately $3,851,815.44. The disclosure for this sale can be found here. Insiders sold 43,524 shares of company stock valued at $24,871,960 in the last three months. Corporate insiders own 2.18% of the company’s stock.

IDEXX Laboratories Stock Down 1.1 %

Shares of NASDAQ:IDXX opened at $497.79 on Monday. The company’s fifty day moving average is $546.90 and its 200-day moving average is $508.17. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.17 and a current ratio of 1.57. IDEXX Laboratories, Inc. has a 52 week low of $372.50 and a 52 week high of $583.39. The company has a market capitalization of $41.34 billion, a PE ratio of 49.43, a P/E/G ratio of 3.83 and a beta of 1.26.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Monday, February 5th. The company reported $2.32 EPS for the quarter, beating analysts’ consensus estimates of $2.12 by $0.20. The firm had revenue of $901.60 million for the quarter, compared to analyst estimates of $891.88 million. IDEXX Laboratories had a net margin of 23.08% and a return on equity of 71.66%. The company’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same period in the previous year, the business earned $2.05 earnings per share. Equities research analysts predict that IDEXX Laboratories, Inc. will post 11.15 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.